HCA Healthcare (NYSE:HCA) Price Target Raised to $431.00

HCA Healthcare (NYSE:HCA) had its price target upped by research analysts at Wells Fargo & Company from $412.00 to $431.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential downside of 9.11% from the company’s current price.

Several other equities analysts have also recently issued reports on the company. KeyCorp raised their price objective on HCA Healthcare from $465.00 to $475.00 and gave the stock an “overweight” rating in a research note on Monday, October 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of HCA Healthcare in a research note on Monday, October 27th. Royal Bank Of Canada lifted their target price on HCA Healthcare from $449.00 to $482.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. Robert W. Baird upped their price objective on shares of HCA Healthcare from $380.00 to $423.00 and gave the company a “neutral” rating in a research note on Thursday, August 14th. Finally, Zacks Research raised shares of HCA Healthcare from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, HCA Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $474.53.

HCA Healthcare Trading Up 0.1%

Shares of NYSE HCA traded up $0.57 during midday trading on Thursday, reaching $474.18. 339,671 shares of the stock were exchanged, compared to its average volume of 1,492,465. The company has a market capitalization of $108.21 billion, a P/E ratio of 18.31, a P/E/G ratio of 1.38 and a beta of 1.41. HCA Healthcare has a 52-week low of $289.98 and a 52-week high of $479.43. The stock has a 50 day moving average price of $431.29 and a 200-day moving average price of $394.54.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Friday, October 24th. The company reported $6.96 EPS for the quarter, beating the consensus estimate of $5.64 by $1.32. The company had revenue of $19.16 billion during the quarter, compared to analysts’ expectations of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. On average, analysts forecast that HCA Healthcare will post 24.98 earnings per share for the current year.

Insider Activity

In other news, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the sale, the executive vice president directly owned 31,503 shares of the company’s stock, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael R. Mcalevey sold 3,892 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the transaction, the executive vice president owned 3,487 shares of the company’s stock, valued at approximately $1,652,105.73. This represents a 52.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 1.30% of the company’s stock.

Institutional Trading of HCA Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sovran Advisors LLC boosted its holdings in HCA Healthcare by 1.0% during the 3rd quarter. Sovran Advisors LLC now owns 2,278 shares of the company’s stock worth $1,063,000 after acquiring an additional 22 shares during the last quarter. Centerpoint Advisors LLC boosted its position in HCA Healthcare by 11.0% during the third quarter. Centerpoint Advisors LLC now owns 222 shares of the company’s stock worth $95,000 after purchasing an additional 22 shares during the period. Cary Street Partners Financial LLC increased its position in shares of HCA Healthcare by 3.9% during the third quarter. Cary Street Partners Financial LLC now owns 590 shares of the company’s stock valued at $251,000 after buying an additional 22 shares during the period. Angeles Wealth Management LLC boosted its position in shares of HCA Healthcare by 2.4% in the third quarter. Angeles Wealth Management LLC now owns 1,014 shares of the company’s stock valued at $432,000 after acquiring an additional 24 shares during the period. Finally, Hemington Wealth Management increased its holdings in HCA Healthcare by 11.0% during the 3rd quarter. Hemington Wealth Management now owns 253 shares of the company’s stock worth $107,000 after acquiring an additional 25 shares during the period. 62.73% of the stock is currently owned by institutional investors and hedge funds.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.